Published in Physician Law Weekly, February 14th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Active Biotech.
Report 1: Active Biotech (ACTI.ST) announced the successful completion of three clinical phase I studies of Anyara for the treatment of advanced non-small cell lung cancer (NSCLC), renal cell cancer (RCC) and pancreatic cancer (PC).
These studies confirm that Anyara has now demonstrated pharmacological proof of concept.
"These important results mean that the Anyara concept of tumor treatment has been fully validated also in man. In addition, the results...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly